Floatz logo

SOMATOSTATIN

Upper Digestive Tract Disorder

Changhai Hospitalprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Upper Digestive Tract Disorder cohort.

Asset / SponsorPhaseRating
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)
Changhai Hospital
Phase 4BB

Same molecule, other indications

SOMATOSTATIN is also rated in:

cirrhosis of liverActive
BB
Indicative · Phase 4
64 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative · Phase 3
54 / 100
View asset →
prostate neoplasmDormant
C
Indicative · Phase 1
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →